<div id="readability-page-1">04:01 PM EST, 11/07/2025 (MT Newswires) -- Health care stocks edged lower late Friday afternoon, with the NYSE Health Care Index shedding 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.2%.The iShares Biotechnology ETF (IBB) was shedding 1%.In corporate news, Gilead Sciences (GILD) shares dropped 4.7% after the company said a phase 3 trial comparing its drug Trodelvy with chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer did not meet the primary endpoint of progression-free survival.Moderna (MRNA) continues to target cash breakeven in 2028, banking on its ongoing cost reductions and revenue growth from geographic expansion and new product launches, Morgan Stanley said in a Friday note. The firm maintained its equalweight rating on Moderna but adjusted its price target to $30 from $32. Moderna shares were up 0.1%.Globus Medical (GMED) can continue delivering cash flow and has the ability to compound profits higher, BofA Securities said in a Thursday note. BofA upgraded the stock to buy from neutral and raised its price target to $91 from $65. Globus shares surged 36%.Haemonetics ( HAE ) is adopting a more cautious guidance approach following a rebound in plasma collection volumes, BofA said Thursday in a report. BofA upgraded Haemonetics ( HAE ) to neutral from underperform and raised its price objective to $75 from $58. Haemonetics ( HAE ) shares rose 2.2%. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

MRNA

吉利德科学

Globus医疗

医疗保健股票在周五晚间下跌，纽约证券交易所医疗保健指数下跌 0.1%。吉利德科学的股票下跌 4.7%，因 Trodelvy 的试验未能达到其主要终点。Moderna 计划在 2028 年前实现现金盈亏平衡，目标价格调整至 30 美元。Globus Medical 被上调至买入评级，股价飙升 36%。Haemonetics 被上调至中性评级，股价上涨 2.2%

板块更新：医疗保健类股在下午晚些时候有所回落